Mandate

Vinge advises EQT on its EUR 890 million sale of Dellner Couplers to Wabtec

March 19, 2025 M&A

Vinge together with Milbank advises the EQT VIII fund (“EQT”) on its sale of Dellner Couplers (“Dellner”), a leading provider of train connection systems for passenger rail, to Wabtec Corporation (a fortune 500 company listed on the New York Stock Exchange, NYSE: WAB). The transaction values Dellner at approximately EUR 890 million. The transaction is subject to customary conditions and regulatory approvals.

Dellner Couplers is a global leader in train connection systems, providing safety-critical components and services to rail manufacturers and operators worldwide. Founded in 1941 in Vika, Sweden, the Company has grown from a family-owned business into one of the most trusted partners of the global rail industry with a strong presence across Europe, North America, and Asia. Its advanced product portfolio includes couplers, gangways, dampers, and aftermarket services, supporting reliable and efficient rail transportation. Dellner has 17 subsidiaries around the world and more than 1,200 employees globally.

EQT was advised by J.P. Morgan Securities Plc, Milbank, Vinge and EY.

Vinge's team primarily consisted of Christina Kokko, Samra Tesser, Linus Adolfsson and Ian Linde.

Read the clients press release here.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025